Source fact
us-gaap:Revenues
0000078003-26-000095
Health Care · PFE
Pfizer
Reported results, filing history, and direct access to the source documents.
LATEST QUARTERLY REPORT
10-Q · Period ended 2026-06-28
Filed 2026-08-04. Values below belong to this filing, not a rolling twelve-month estimate. Duration figures may cover a full year or year-to-date period.
Source fact
us-gaap:NetIncomeLoss
0000078003-26-000095
Source fact
us-gaap:Assets
0000078003-26-000095
Source fact
us-gaap:NetCashProvidedByUsedInOperatingActivities
0000078003-26-000095
LATEST ANNUAL REPORT
10-K · Period ended 2025-12-31
Filed 2026-02-26. Values below belong to this filing, not a rolling twelve-month estimate. Duration figures may cover a full year or year-to-date period.
Source fact
us-gaap:Revenues
0000078003-26-000026
Source fact
us-gaap:NetIncomeLoss
0000078003-26-000026
Source fact
us-gaap:Assets
0000078003-26-000026
Source fact
us-gaap:NetCashProvidedByUsedInOperatingActivities
0000078003-26-000026
Disclosure timeline
Latest tracked 10-K, 10-Q, amendments, and earnings-related 8-K Item 2.02 filings. Amendments are listed but do not automatically replace the original report's facts.
10-Q · Period ended 2026-06-28 →Accession 0000078003-26-000095
8-K · Results of operations disclosure →Accession 0000078003-26-000094
10-Q · Period ended 2026-03-29 →Accession 0000078003-26-000054
8-K · Results of operations disclosure →Accession 0000078003-26-000053
10-K · Period ended 2025-12-31 →Accession 0000078003-26-000026
8-K · Results of operations disclosure →Accession 0000078003-26-000005
10-Q · Period ended 2025-09-28 →Accession 0000078003-25-000150
8-K · Results of operations disclosure →Accession 0000078003-25-000149
10-Q · Period ended 2025-06-29 →Accession 0000078003-25-000138
8-K · Results of operations disclosure →Accession 0000078003-25-000136
10-Q · Period ended 2025-03-30 →Accession 0000078003-25-000114
8-K · Results of operations disclosure →Accession 0000078003-25-000111
10-K · Period ended 2024-12-31 →Accession 0000078003-25-000054
8-K · Results of operations disclosure →Accession 0000078003-25-000017
10-Q · Period ended 2024-09-29 →Accession 0000078003-24-000191
8-K · Results of operations disclosure →Accession 0000078003-24-000188
10-Q · Period ended 2024-06-30 →Accession 0000078003-24-000166
8-K · Results of operations disclosure →Accession 0000078003-24-000155
10-Q · Period ended 2024-03-31 →Accession 0000078003-24-000107
8-K · Results of operations disclosure →Accession 0000078003-24-000103
10-K · Period ended 2023-12-31 →Accession 0000078003-24-000039
8-K · Results of operations disclosure →Accession 0000078003-24-000017
8-K · Results of operations disclosure →Accession 0001193125-23-294930
10-Q · Period ended 2023-10-01 →Accession 0000078003-23-000115
Read with context.
These are automatically extracted filing facts, not a complete financial review. Different companies and report types may use different reporting periods and accounting definitions. Missing values are not zero. No stock prices, earnings forecasts, or buy/sell ratings are provided.
All SEC filings for this company · Sources, coverage, and methodology
For education and research only. Not investment advice. Verify original filings before making decisions.